MENLO PARK, Calif.–(BUSINESS WIRE)–#personalis–Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced the closing of its initial public offering of 9,109,725 shares of common stock at […]

In an interview with Cheddar TV, IPO Edge Editor-in-Chief John Jannarone argues that workplace messenger service Slack should find support in coming days thanks to a limited number of likely sellers and a business […]

BEDFORD, Mass.–(BUSINESS WIRE)–Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company that is pioneering a new way to treat the underlying cause of genetic diseases by precisely upregulating protein expression, today […]

NEW YORK–(BUSINESS WIRE)–Prevail Therapeutics Inc. (Nasdaq: PRVL) (Prevail), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with neurodegenerative disorders, today announced the pricing of its initial public […]

BEDFORD, Mass.–(BUSINESS WIRE)–Stoke Therapeutics, Inc., a biotechnology company that is pioneering a new way to treat the underlying cause of genetic diseases by precisely upregulating protein expression, today announced the pricing […]

  It’s always worth watching measures of risk appetite when evaluating equities, and one such gauge recently perked up: the ratio of lumber to gold. That could suggest more upside […]

In an interview with Cheddar TV, IPO Edge Editor-in-Chief John Jannarone lays out the bull case for online pet supply heavyweight Chewy, which begins trading Friday after pricing at $22 a share Thursday night. […]

PALO ALTO, Calif.–(BUSINESS WIRE)–GigCapital2, Inc. (NYSE: GIX.U) (www.GigCapital2.com) (the “Company”) today announced that the underwriters, pursuant to the terms of the underwriting agreement, exercised in full their previously announced option […]

NEW YORK–(BUSINESS WIRE)–Fiverr International Ltd. (“Fiverr”), announced today the pricing of its initial public offering of 5,263,158 ordinary shares at a public offering price of $21.00 per share. The underwriters […]

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Seres Therapeutics, Inc. (Nasdaq: MCRB) (“Seres”), a leading microbiome therapeutics platform company developing a novel class of biological drugs that are designed to treat disease by restoring the […]